Frontage Holdings Corporation has announced a change in its management effective July 15, 2025. Mr. Jun (Henry) Gao will resign from his position as Chief Financial Officer, and Ms. Huan Wang will step in as the interim Chief Financial Officer. Ms. Wang, who has significant experience in finance within the pharmaceutical and CRO industry, is currently the Vice President Finance of Frontage Laboratories, Inc., a wholly owned subsidiary of the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.